A novel anti-pruritic: Topical co-administration of high molecular weight hyaluronan (HMWH) with protamine, a transdermal transport enhancer.

Publisher: Sage Publications Inc Country of Publication: United States NLM ID: 101242662 Publication Model: Print Cited Medium: Internet ISSN: 1744-8069 (Electronic) Linking ISSN: 17448069 NLM ISO Abbreviation: Mol Pain Subsets: MEDLINE

Publication: 2016- : Thousand Oaks, CA : Sage Publications Inc.
Original Publication: [London] : BioMed Central, 2005-

Hyaluronic Acid*/pharmacology ; Hyaluronic Acid*/chemistry ; Rats, Sprague-Dawley* ; Administration, Cutaneous* ; Protamines*/pharmacology; Animals ; Male ; Female ; Rats ; Molecular Weight ; Serotonin/metabolism ; Administration, Topical

Pruritis, the sensation of itch, is produced by multiple substances, exogenous and endogenous, that sensitizes specialized sensory neurons (pruriceptors and pruri-nociceptors). Unfortunately, many patients with acute and chronic pruritis obtain only partial relief when treated with currently available treatment modalities. We recently demonstrated that the topical application of high molecular weight hyaluronan (HMWH), when combined with vehicles containing transdermal transport enhancers, produce potent long-lasting reversal of nociceptor sensitization associated with inflammatory and neuropathic pain. In the present experiments we tested the hypothesis that the topical formulation of HMWH with protamine, a transdermal transport enhancer, can also attenuate pruritis. We report that this topical formulation of HMWH markedly attenuates scratching behavior at the nape of the neck induced by serotonin (5-hydroxytryptamine, 5-HT), in male and female rats. Our results support the hypothesis that topical HMWH in a transdermal transport enhancer vehicle is a strong anti-pruritic.
Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Br J Anaesth. 2008 Sep;101(3):311-9. (PMID: 18611915)
Curr Opin Pharmacol. 2019 Jun;46:122-142. (PMID: 31299512)
Mov Disord. 1989;4(4):342-4. (PMID: 2682216)
J Allergy Clin Immunol. 2024 Apr;153(4):904-912. (PMID: 38103700)
Eur J Pharmacol. 2008 Jan 28;579(1-3):390-4. (PMID: 18037400)
Nat Commun. 2014 Jun 20;5:4122. (PMID: 24947823)
PLoS One. 2013 Nov 18;8(11):e79123. (PMID: 24260163)
Pharm Dev Technol. 2019 Jun;24(5):630-638. (PMID: 30457418)
Vet Res Forum. 2021 Spring;12(2):143-148. (PMID: 34345379)
J Pharmacol Exp Ther. 2003 Jul;306(1):245-52. (PMID: 12682216)
Curr Opin Neurobiol. 2022 Aug;75:102573. (PMID: 35689909)
Pflugers Arch. 2013 Dec;465(12):1671-85. (PMID: 23636773)
Med Sci (Basel). 2019 Apr 18;7(4):. (PMID: 31003539)
IEEE Trans Ultrason Ferroelectr Freq Control. 2023 Oct;70(10):1286-1294. (PMID: 37647181)
J Am Acad Dermatol. 2022 Jan;86(1):1-14. (PMID: 34428534)
Joint Bone Spine. 2005 Oct;72(5):359-71. (PMID: 16214069)
J Inflamm (Lond). 2016 Jun 22;13:20. (PMID: 27340371)
Acta Derm Venereol. 2019 Apr 1;99(5):469-506. (PMID: 30931482)
J Biol Chem. 2013 May 3;288(18):12818-27. (PMID: 23508958)
Neurosci Res. 1999 Nov;35(2):77-83. (PMID: 10616911)
Pain. 2006 Sep;124(1-2):50-8. (PMID: 16697529)
J Pharmacol Exp Ther. 2003 Jul;306(1):355-62. (PMID: 12682218)
Acta Derm Venereol. 2020 Jan 7;100(2):adv00023. (PMID: 31940043)
Clin J Pain. 2001 Mar;17(1):2-10. (PMID: 11289084)
J Pharm Sci. 2013 Nov;102(11):4109-20. (PMID: 24018779)
Pain. 2023 Dec 1;164(12):2653-2664. (PMID: 37467181)
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):780. (PMID: 33689184)
Int Urol Nephrol. 2020 Jun;52(6):1155-1165. (PMID: 32383050)
J Allergy Clin Immunol. 2023 Jul;152(1):11-23. (PMID: 37201903)

R01 AR075334 United States AR NIAMS NIH HHS

Keywords: 5-hydroxytryptamine; Hyaluronan; itch; topical anti-pruritic; transdermal transporter

9004-61-9 (Hyaluronic Acid)
0 (Protamines)
333DO1RDJY (Serotonin)

Date Created: 20240510 Date Completed: 20240510 Latest Revision: 20240513

20240513

PMC11088296

10.1177/17448069241254455

38728068